Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$193.98 USD
-2.44 (-1.24%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $193.81 -0.17 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
Ascendis Pharma A/S's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ASND 193.98 -2.44(-1.24%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Other News for ASND
Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pharmaceuticals Inc
Is ASND likely to continue higher? 50 Day Moving Average Support shows up after sliding 0.64%
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
Wedbush sees no threat to Ascendis' Yorvipath from competitor data